financetom
Business
financetom
/
Business
/
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025 12:13 PM

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22.

The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028

Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc ( MDT ). and Abbott Laboratories ( ABT ) .

The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.

Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.

Also Read: Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees ‘Opportunity To Restore Free Expression’

The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.

Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.

In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.

Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company’s proprietary ADAPT tissue technology, Miksic writes.

For FY25, the analyst estimates the company to report a loss of $(1.30) per share.

Price Action: AVR shares are trading higher by 2.67% to $5.760 at last check Tuesday.

Read now:

AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025

Anteris logo courtesy of company

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Johnson & Johnson Says Nipocalimab Granted FDA Priority Review in Myasthenia Gravis
Johnson & Johnson Says Nipocalimab Granted FDA Priority Review in Myasthenia Gravis
Jan 9, 2025
08:44 AM EST, 01/09/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that the US Food and Drug Administration has granted priority review designation to its biologics license application for nipocalimab to treat antibody positive patients with generalized myasthenia gravis. The company said its application was supported by the results of a phase 3 study, which showed...
UnitedHealth Shareholders Call for Report to Evaluate Risks of Healthcare Denials
UnitedHealth Shareholders Call for Report to Evaluate Risks of Healthcare Denials
Jan 9, 2025
08:44 AM EST, 01/09/2025 (MT Newswires) -- UnitedHealth Group ( UNH ) shareholders have proposed that the health insurance company report on public health-related costs and macroeconomic risks caused by practices that limit or delay access to healthcare. The shareholder proposal said the report should evaluate how the company's practices impact access to healthcare and patient outcomes. It said the...
Market Chatter: Lion Electric Plans to Focus On Buses Rather Than Trucks In Bid To Attract Buyer
Market Chatter: Lion Electric Plans to Focus On Buses Rather Than Trucks In Bid To Attract Buyer
Jan 9, 2025
08:47 AM EST, 01/09/2025 (MT Newswires) -- Quebec electric-vehicle maker Lion Electric Co. ( LEVGQ ) (LEV.TO, LEV) wants to pause building trucks and focus instead on school buses as part of a restructuring plan that would return all manufacturing operations to the province, The Canadian Press has reported. The report noted the struggling company, which entered creditor protection last...
Krispy Kreme Promotes Nicola Steele to COO
Krispy Kreme Promotes Nicola Steele to COO
Jan 9, 2025
08:48 AM EST, 01/09/2025 (MT Newswires) -- Krispy Kreme (DNUT) said Thursday it has promoted Nicola Steele to chief operating officer. Steele, who serves as president of Krispy Kreme Australia and New Zealand, will oversee global operations, the company said. Krispy Kreme also said it has named Raphael Duvivier president of international. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved